Patients, clinicians and advocates spoke in support of H2532 to create a regulated framework for therapeutic psilocybin treatment centers, saying clinical trials and patient experience point to benefits for treatment‑resistant depression, PTSD and other conditions.

Graham Moore, a patient and caregiver and lead educator with the nonprofit Mass Healing, recounted family losses and said, “A growing body of research shows that psilocybin can be a safe and effective treatment for a number of behavioral health conditions. This bill would allow for regulated access.” He described veterans and others who sought treatment and testified to life‑changing outcomes.

Ashley Mahoney, a licensed mental health counselor and certified psychedelic‑assisted therapy practitioner, supported a regulatory framework but warned of cost and equity risks. She urged that the program be designed “ethically with explicit goal of public health equity, not profit maximization.” Ms. Mahoney noted Oregon’s experience where some treatments can cost up to $10,000 per session and said Massachusetts should learn from that example to avoid unaffordable care.

Supporters asked the committee to advance H2532 with affordability, accessibility and training standards included; they emphasized safeguards and clinician oversight. No vote was taken at the hearing.